After immunization, the proportion of CD4+ T lymphocytes in the SPP adjuvant (10, 30 and 50 mg/mL) and OA groups was significantly higher than that in the BC group (p < 0.05) at all the time points. The gene discussed is CD4; the disease is breast cancer.